320 related articles for article (PubMed ID: 16604818)
1. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
4. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
7. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
9. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
[TBL] [Abstract][Full Text] [Related]
10. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
Kappos L; Polman C; Pozzilli C; Thompson A; Beckmann K; Dahlke F;
Neurology; 2001 Dec; 57(11):1969-75. PubMed ID: 11739811
[TBL] [Abstract][Full Text] [Related]
11. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
12. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
[TBL] [Abstract][Full Text] [Related]
14. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
[TBL] [Abstract][Full Text] [Related]
15. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
16. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
Portaccio E; Amato MP
CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
[TBL] [Abstract][Full Text] [Related]
17. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Arnason BG
J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
[TBL] [Abstract][Full Text] [Related]
19. History of modern multiple sclerosis therapy.
Lublin F
J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
[TBL] [Abstract][Full Text] [Related]
20. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]